Edition:
United Kingdom

Oasmia Pharmaceutical AB (OASM.OQ)

OASM.OQ on NASDAQ Stock Exchange Capital Market

4.30USD
19 Nov 2018
Change (% chg)

-- (--)
Prev Close
$4.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
14,351
52-wk High
$5.70
52-wk Low
$0.85

Latest Key Developments (Source: Significant Developments)

Oasmia Pharmaceutical: New US Patent Granted
12:00pm GMT 

Nov 20 (Reuters) - Oasmia Pharmaceutical AB ::NEW U.S. PATENT RELATED TO OASMIA PHARMACEUTICAL’S NANOTECHNOLOGY PLATFORM XR17 HAS BEEN GRANTED.PATENT WILL BE VALID THROUGH 2036..PATENT WILL BE PUBLISHED ON NOVEMBER 27(TH), 2018..OASMIA PHARMACEUTICAL - UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO) HAS ISSUED A NOTIFICATION OF ALLOWANCE OF A PATENT.  Full Article

Oasmia Pharmaceutical Granted US Patent Related To Nanotechnology Platform XR17
7:30am GMT 

Nov 20 (Reuters) - OASMIA PHARMACEUTICAL AB ::REG-NEW U.S. PATENT RELATED TO OASMIA PHARMACEUTICAL’S NANOTECHNOLOGY PLATFORM XR17 HAS BEEN GRANTED.PATENT WILL BE PUBLISHED ON NOVEMBER 27(TH), 2018..PATENT WILL BE VALID THROUGH 2036..  Full Article

Oasmia says Phase II study with Doxophos well tolerated
Wednesday, 3 Oct 2018 

Oct 3 (Reuters) - Oasmia Pharmaceutical AB says::Overall response rate data from the (RXE(1)) Phase II study conducted in the US and Sweden met its primary end points and treatment with Doxophos Vet was generally well tolerated..Assessment is that the positive safety and efficacy data will be sufficient for AdvaVet Inc. to seek conditional approval for Doxophos Vet in the US in the first half of 2019..  Full Article

Oasmia Pharma Q1 operating loss narrows slightly yr/yr
Friday, 31 Aug 2018 

Aug 31 (Reuters) - Oasmia Pharmaceutical AB ::Q1 CONSOLIDATED NET SALES AMOUNTED TO TSEK 128 COMPARED TO TSEK 20 IN Q1 PREVIOUS YEAR.SAYS OPERATING LOSS WAS TSEK 26,572 COMPARED TO TSEK 28,421 IN Q1 PREVIOUS YEAR.  Full Article

Oasmia Pharmaceutical Says May Offer, Issue, Sell Up to US$25 Mln Shares
Monday, 30 Apr 2018 

April 30 (Reuters) - Oasmia Pharmaceutical AB ::OASMIA PHARMACEUTICAL AB -MAY OFFER, ISSUE, SELL UP TO US$25 MILLION OF SHARES/ADSS, NUMBER OF WARRANTS TO PURCHASE ORDINARY SHARES, COMBINATION OF SECURITIES.  Full Article

Oasmia Pharmaceutical Q2 operating loss shrinks
Friday, 1 Dec 2017 

Dec 1 (Reuters) - Oasmia Pharmaceutical Ab ::OASMIA PHARMACEUTICAL AB Q2 ‍CONSOLIDATED NET SALES AMOUNTED TO TSEK 1,651 COMPARED TO TSEK 56 IN THE SECOND QUARTER THE PREVIOUS YEAR ​.OASMIA PHARMACEUTICAL AB Q2 ‍OPERATING LOSS WAS TSEK 22,129 COMPARED TO TSEK 35,867 IN THE SECOND QUARTER THE PREVIOUS YEAR ​.  Full Article

Oasmia Q4 operating loss widens
Thursday, 8 Jun 2017 

June 8 (Reuters) - Oasmia Pharmaceutical Ab ::Q4 consolidated net sales amounted to 44,000 SEK compared to 59,000 in q4 previous year.Q4 operating loss was 37 mln SEK compared to a loss of 31 mln SEK in q4 previous year.Says the board does not intend to propose any dividends for the financial year May 1, 2016 – April 30, 2017..  Full Article